Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

This study has been completed.
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT01607450
First received: May 21, 2012
Last updated: January 19, 2016
Last verified: January 2016

May 21, 2012
January 19, 2016
May 2010
December 2012   (final data collection date for primary outcome measure)
Myocardial Glucose Uptake. [ Time Frame: After 12 hours of glucagon-like peptide 1 (GLP-1) exposure ] [ Designated as safety issue: No ]
Myocardial glucose uptake measured using 18FDG PET, quantified using a 3-compartment model with a lumped constant of 1.0.
Dose dependent myocardial glucose uptake. [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
Myocardial glucose uptake will be quantified using a 3-compartment model, according to the methods of Morita and colleagues with a lumped constant of 1.0.
Complete list of historical versions of study NCT01607450 on ClinicalTrials.gov Archive Site
  • Myocardial Blood Flow [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
    Myocardial perfusion derived from acetate kinetics
  • Myocardial Total Oxidation Rate [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
    MVO2 derived from acetate kinetics
  • Cardiac Index [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
    Impedance cardiography-derived measurement of cardiac index, assessed following 12 hour exposure to treatment condition concurrent with the PET measurements.
  • GLP-1 Concentrations [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
    Achieved GLP-1 concentrations at the end of the 12 hour treatment exposure
  • Dose dependent Myocardial blood flow. [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
  • Myocardial total oxidation with a given dose of GLP-1 [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
  • Systemic hemodynamics measured by impedence cardiography [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
  • Circulating metabolic substrates and hormones [ Time Frame: After 12 hours of GLP-1 exposure ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

The objective of this proposal is to provide quantitative dose-response data for effects of GLP-1 on myocardial glucose uptake in healthy control subjects and obese type 2 diabetic subjects, in support of the design of later studies evaluating therapeutic applications of GLP-1 to heart disease.

Aim 1: To measure the effects of GLP-1 infusion on myocardial fuel selection in lean healthy humans under fasting (fatty acid-dominant) conditions. Four groups of 10 lean healthy subjects will be studied during infusions of 0 (saline control), 0.5, 1.5, and 4.0 pmol/kg/min GLP-1 (one study per subject). Cardiac metabolism will be measured using PET, using a dual-tracer approach which allows measurement of myocardial glucose uptake (the primary endpoint) along with total oxidation rate and myocardial perfusion (secondary endpoints). In concert with measures of circulating metabolites and regulatory hormones, the investigators will produce the most comprehensive assessment of actions of GLP-1 on myocardial metabolism in humans to date. Effects of each dose will be compared to the saline control, plus the investigators will combine all data and use nonlinear curve-fitting to derive sensitivity (ED50) and maximal responses for GLP-1 effects on myocardial glucose uptake.

Aim 2: To measure the effects of GLP-1 infusion on myocardial fuel selection in obese type 2 diabetic humans under fasting (fatty acid-dominant) conditions Four groups of 10 obese type 2 diabetic subjects will be studied during infusions of 0, 0.5, 1.5, and 4.0 pmol/kg/min GLP-1 as under Aim 1. Analyses will be parallel to those described under Aim 1. Results from Aims 1 and 2 will be combined to allow direct comparison of the dose-response between nondiabetic control and type 2 diabetic subjects.

No literature has been published to inform dose selection in the design of clinical trials of GLP-1 for modulation of heart fuel selection. With our expertise and experience in PET measurement of heart metabolism in diabetes, the investigators are uniquely positioned to fill this gap in knowledge. These studies are a necessary preamble to further evaluation of the potential for GLP-1 based treatments in heart disease.

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
  • Type 2 Diabetes Mellitus
  • Healthy
  • Drug: GLP-1 Low Dose
    0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study
  • Drug: GLP-1 Mid-Range Dose
    1.5mmol/kg/min for 12 hours prior to PET study
  • Drug: GLP-1 High Dose
    4.0mmol/kg/min GLP-1 for 12 hours prior to PET study
  • Drug: Saline
    Normal saline placebo infusion for 12 hours prior to PET study
    Other Name: Normal Saline
  • Saline
    12 hour saline (control) infusion prior to PET study
    Intervention: Drug: Saline
  • Experimental: GLP-1 Low dose
    GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study
    Intervention: Drug: GLP-1 Low Dose
  • Experimental: GLP-1 Mid-Range Dose
    GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study
    Intervention: Drug: GLP-1 Mid-Range Dose
  • Experimental: GLP-1 High Dose
    GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study
    Intervention: Drug: GLP-1 High Dose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-60
  • Lean subjects will be defined as having a BMI <25 kg/m2, in good general health, taking no regular medications
  • Diabetic subjects will be obese (BMI >30 kg/m2 but <40 kg/m2), HbA1c 7.0-10.0%, treated with diet and exercise plus oral agents or injected insulin. All diabetic subjects will be treated with injected insulin for 2 weeks prior to study, to avoid potential confounding effects of other antidiabetic agents.

Exclusion Criteria:

  • Chronic illnesses or infections (other than type 2 diabetes)
  • Known coronary artery disease or abnormal ECG on screening evaluation
  • Blood pressure > 160/100 mmHg on two occasions during screening evaluations. Current use of 3 or fewer blood pressure medications with blood pressure below this cutpoint will be acceptable.
  • Total cholesterol > 240 mg/dL. Current use of 2 or fewer lipid lowering agents with cholesterol below this cutpoint will be acceptable.
  • Diabetic subjects: Treatment with a GLP-1 agonist or DPP4 inhibitor within the past 6 months
  • Known intolerance to injected GLP-1 agonist
  • Treatment with PPAR gamma agonists currently or within the past 6 months
  • Recognized microvascular complications (retinopathy, nephropathy, neuropathy)
  • Unwillingness or inability to use injected insulin for the purposes of this study
  • Chronic pain or other physical conditions which limit ability to remain supine for the duration of the study protocol
  • History of claustrophobia, musculoskeletal or other factors which would result in an inability to comfortably remain within PET scanner gantry for the duration of the imaging protocol
  • Occupational, investigational or other known radiation exposure which, together with the planned radiologic studies, will result in greater than 500 mrem total exposure in a contiguous 12 month period
  • For female participants, current pregnancy
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01607450
1010002497, R21HL092799
Yes
Not Provided
Not Provided
Indiana University
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Kieren J Mather, MD Indiana University
Indiana University
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP